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Abstract
Aim: To analyze the management of newborns after
major surgery receiving morphine subcutaneously and to
identify possible side effects.
Methods: Morphine was administered via a subcutane-
ous catheter (Insuflon) in 20 newborns after major sur-
gery. Side effects like hypotension, pain during morphine
administration and local infection were noted. Morphine
dose was adjusted according to the hospital guidelines
with the Neonatal Infant Pain Score (NIPS) and the
Finnegan withdrawal score.
Results: Surgery was performed at the median age of 38
5/7 weeks (range: 32 1/7–49 5/7 weeks). Before starting
subcutaneous morphine administration, patients
received intravenous morphine for a median of two
weeks (range six days to seven weeks). All patients
showed good pain relief with no severe side effects.
Three patients reacted with crying to the first dose of
subcutaneous morphine. No other side effects occurred.
Conclusion: Subcutaneous application of morphine with
the Insuflon catheter is an alternative to intravenous
treatment of postoperative pain in neonates. In this small
group pain relief was good and side effects were
harmless.
Keywords: Cannula; neonate; postoperative pain; sub-
cutaneous injection.
Introduction
Morphine therapy in newborns is a controversial issue in
recent years because of the side effects of this drug and
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outcome studies which showed that intermittent boluses
of open-label morphine were associated with an
increased rate of composite outcome (death, severe
intraventricular haemorrhage, periventricular leukomala-
cia) w1, 4x. In addition, data from a recent study suggest
that early surgery may lead to increased pain sensitivity
in older children w9x. Whereas for short-term therapy,
peripheral intravenous catheters are routinely used, cen-
tral venous lines are usually required for long-term ther-
apy, which notably increase the risk of catheter-related
bloodstream infections and thrombosis w5, 7x.
No published data exist so far on subcutaneous
administration of morphine for postoperative pain treat-
ment in newborns. The aim of this study was to analyse
our data of newborns treated with morphine via a sub-
cutaneous catheter.
Materials and methods
A cohort of 20 consecutive newborns receiving morphine after
complex visceral or cardiac surgery was analysed. Following
removal of the central venous line, morphine was administered
subcutaneously as a bolus injection via a subcutaneous catheter
(Insuflon; Unomedical A/S, Lynge, Denmark) for a total of six
doses daily. The Insuflon consists of a Teflon catheter with a
length of 19 mm (Figure 1). To make the insertion painless,
EMLA cre`me was used as a local anesthetic. Most devices
were inserted in the ventral thigh, changing the side routinely
once a week unless adverse effects were noted. The application
was performed by the nursing staff according to the instruction
of the manufacturer. Patient’s pain was assessed by the neo-
natal infant pain scale (NIPS). This pain score was developed
and validated for procedural pain and includes facial expression,
crying, breathing pattern, arms, legs and state of arousal. We
used this score because the nursing staff is very well trained in
applying the score. In patients on morphine for longer than two
weeks, the Finnegan score was applied as well w3, 7x. Morphine
dose was adjusted if the pain score was above four, according
to the guidelines, or the Finnegan score was above eight in three
consecutive assessments. The subcutaneous doses of mor-
phine were calculated by dividing the daily dose of intravenous
morphine by six. Morphine doses were reduced by 25% every
second day if the NIPS score was four or less, according to our
hospital pain relief reduction guidelines. In our institution mor-
phine treatment will stop in one step if the patient requires five
or less days of treatment; otherwise the morphine will be grad-
ually decreased. If the pain score was higher than four the dose
was increased back to the previous level and left for the next
24 h before the next reduction. Blood pressure was monitored
by peripheral measurements 15–20 min after injection during the
first three times of subcutaneous morphine application and
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Figure 1 Principle of the subcutaneous catheter (Insuflon).
Table 1 Baseline characteristics of the 20 patients.
Median Range
Birth weight (g) 3035 2020–4150
Age at first subcutaneous application (weeks gestation) 41.3 36–49 3/7
Duration of therapy (days) 7.5 2–17
IV Morphine therapy postoperative (weeks) 2 1–6.5
Initial dose (mg/kg/day) 0.1 0.01–0.3
Minimal dose before stop (mg/kg/day) 0.045 0.005–0.3
Application interval (h) 8 4–24
when the dose of morphine was increased. Side effects like
hypotension, apnea, local infection or local bleeding were
monitored.
The study was approved by the hospital Ethics Committee.
Data are expressed as median and range, as appropriate.
Results
Baseline characteristics of the 20 newborns included in
the study are summarized in Table 1. In 15 and 5 new-
borns complex cardiac surgery and visceral surgery,
respectively, was performed at the median age of 38
5/7 weeks’ gestation (range: 32 1/7–49 5/7 weeks).
Underlying diseases were: in five patients hypoplastic left
heart syndrome; six patients with transposition of the
great vessels; one patient each with Ebstein’s anomaly,
double outlet left ventricle, hypoplastic aortic arch and
truncus arteriosus; two with diaphragmatic hernia and
one patient each with sacral teratoma, intestinal volvolus
and esophageal atresia. The Insuflon catheter was
placed in the thigh in 19 newborns and in the abdominal
wall in the remaining newborn. One newborn developed
a small amount of bleeding at the insertion site. No other
local side effects, like swelling or inflammation, were
observed. Three out of 20 newborns, requiring increased
morphine doses, reacted with crying and retraction of the
leg during application of the first subcutaneous injection.
None of the newborns showed hypotension or apnea.
Withdrawal symptoms like sweating, nervousness, and
crying were seen in three out of 20 patients and treated
according to the guidelines described before.
Discussion
Although morphine is the most important medication to
treat postoperative pain in newborns, insufficient infor-
mation exists on subcutaneous administration of this
drug as compared to the intravenous administration.
Results of this study show that subcutaneous morphine
administration through the Insuflon catheter was, in this
small group of patients, easy and safe. Whereas pain
treatment in newborns is still controversial, no doubts
exist about the fact that newborns may well perceive
pain, especially after surgery, and thus treatment is indi-
cated in these young patients. Indeed, Nandi et al. w8x
demonstrated that a considerable maturation of periph-
eral, spinal, and supraspinal afferent pain transmission
occur in the early postnatal period. Besides ethical
aspects, Anand et al. w2x showed that insufficient pain
therapy causes increased morbidity and mortality in new-
borns. However, bolus administration in otherwise
healthy preterm infants has been associated with
increased side effects, particularly hypotension and IVH
w1x. In a recent study by Simons et al. w10x, however,
blood pressure was not influenced by continuous intra-
venous morphine infusion. In agreement with these
results, none of our newborns showed hypotension after
subcutaneous injection. Our findings likely reflect possi-
ble pharmaco-dynamical similarities between continuous
intravenous and subcutaneous administration of mor-
phine, suggesting that these applications may be more
appropriate than bolus intravenous injections. Long-term
use of central venous catheters is associated with seri-
ous side effects like sepsis and thrombosis. Thus, sub-
cutaneous administration could be of great advantages
in this age group. Insufficient data on subcutaneous
application of morphine in children are available, partic-
ularly when newborns are concerned. In one study by
Lamacraft et al. w6x, the effect of subcutaneous admin-
istration of morphine through a 22-gauge butterfly can-
nula for a median of 27 h was investigated in older
children. Our study is the first to report successful long-
term subcutaneous morphine administration in newborn
patients. However, limitations of our study include the
lack of a control group and the small number of patients.
A number of our patients were certainly not suffering
from pain any more but from withdrawal symptoms.
Bernet et al., Long-term subcutaneous morphine administration after surgery in newborns 81
Article in press - uncorrected proof
These symptoms were successfully treated with subcu-
taneous morphine as well. Another question might be
why did we prefer this method instead of oral morphine
treatment. A few of these patients showed malabsorption
caused by either cardiac insufficiency or after abdominal
operation. In our patient group the plasma concentration
seems to be more stable. Another limitation of our study
is that no pharmacokinetic studies were performed in
these newborns and no ventilated patients were
included.
In conclusion, subcutaneous administration of mor-
phine using the Insuflon catheter is a valid alternative
to intravenous treatment of postoperative pain in new-
borns. Larger studies are required to further investigate
the use of subcutaneous morphine administration in the
treatment of pain in newborns, which will also focus on
pharmacokinetics and on patients on mechanical
ventilation.
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